Investigational drug · Phase 2
PD-L1 t-haNK
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
16
Any phase or sponsor naming "PD-L1 t-haNK"
First trial start
2018
Dec 11, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PD-L1 t-haNK", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Urothelial Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Gastric Cancer
- Cervical Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PD-L1 t-haNK" as an intervention, largest first.
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerPivotal-lookingActive, not recruiting
ImmunityBio, Inc.Industry
NCT04390399 · 328 participants (planned) · Start Jul 21, 2020 · Primary completion Oct 13, 2025
Drug: N-803; Aldoxorubicin HCl and 7 more · For: Pancreatic Cancer
Sites: El Segundo, California; Newport Beach, California; East Brunswick, New Jersey · 4 sites in all
ImmunityBio, Inc.Industry
NCT07628062 · 70 participants (planned) · Start Jul 22, 2026 · Primary completion Dec 31, 2030
Drug: Nogapendekin Alfa Inbakicept (NAI); hAd5-HPV Vaccine (IBRX-042) and 2 more · For: HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruiting
ImmunityBio, Inc.Industry
NCT03228667 · 40 participants (planned) · Start Dec 11, 2018 · Primary completion Aug 31, 2029
Drug: N-803 + Pembrolizumab; N-803 + Nivolumab and 10 more · For: Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma and 10 more
Sites: Anchorage, Alaska; Hot Springs, Arkansas; El Segundo, California · 35 sites in all
National Cancer Institute (NCI)NIH
NCT06161545 · 40 participants (planned) · Start Sep 24, 2025 · Primary completion Dec 1, 2026
Drug: PD-L1 t-haNK cells; pembrolizumab and 1 more · For: Stage II Squamous Cell Carcinoma of the Head and Neck; Stage III Squamous Cell Carcinoma of the Head and Neck; Stage IV Squamous Cell Carcinoma of the Head and Neck
Sites: Bethesda, Maryland
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruiting
ImmunityBio, Inc.Industry
NCT06061809 · 34 participants (planned) · Start Aug 7, 2024 · Primary completion Dec 31, 2029
Drug: Bevacizumab; PD-L1 t-haNK and 1 more · For: Glioblastoma
Sites: El Segundo, California; Fullerton, California; Newport Beach, California · 4 sites in all
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT06239220 · 25 participants (planned) · Start Feb 16, 2024 · Primary completion Dec 31, 2026
Drug: PD-L1 t-haNK; Cetuximab and 1 more · For: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer and 3 more
Sites: Boston, Massachusetts · 2 sites in all
- Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaActive, not recruiting
ImmunityBio, Inc.Industry
NCT06334991 · 20 participants · Start Aug 23, 2024 · Primary completion Oct 2027
Drug: CD19 t-haNK · For: Non-Hodgkin Lymphoma Refractory/ Relapsed
Sites: Bloemfontein, South Africa; Johannesburg, South Africa; Pretoria, South Africa
ImmunityBio, Inc.Industry
NCT05618925 · 20 participants (planned) · Start Aug 22, 2025 · Primary completion May 15, 2026
Drug: N803; CD19t-haNK suspension and 3 more · For: Non Hodgkin's Lymphoma Refractory/Relapsed
Sites: Newport Beach, California; Tyler, Texas
National Cancer Institute (NCI)NIH
NCT04847466 · 18 participants · Start Dec 14, 2021 · Primary completion Dec 22, 2025
Drug: N-803; Pembrolizumab and 1 more · For: Gastroesophageal Junction (GEJ) Cancers; Advanced HNSCC
Sites: Bethesda, Maryland
ImmunityBio, Inc.Industry
NCT04050709 · 16 participants · Start Jul 18, 2019 · Primary completion Mar 30, 2021
Drug: PD-L1 t-haNK · For: Locally Advanced Solid Tumor; Metastatic Cancer; Solid Tumor
Sites: El Segundo, California
Newest research
PubMed records naming it or its code names, newest first.
- The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.
Lee CA, Schlom J, Hodge JW, et al. · Cancer Immunol Immunother 2025
- Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.
Moini K, Seery T, Nangia C, et al. · Oncologist 2025
- Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.
Seery T, Sender L, Jafari O, et al. · Front Oncol 2025
- PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP, Padget MR, Donahue RN, et al. · J Immunother Cancer 2020
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.